Beauty sessions may ease anxiety for blood cancer patients in isolation
NCT ID NCT03959007
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether aesthetic therapy sessions (like skincare or makeup) could reduce anxiety and improve quality of life for patients with acute leukemia or those who had a stem cell transplant. These patients are isolated in a protected hospital area for at least 28 days. Researchers compared patients who received three aesthetic therapy sessions with those who did not, using questionnaires to measure anxiety and well-being.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- aesthetic therapy sessions
- What this could lead to
- If it works, this could show that aesthetic therapy helps reduce anxiety and improve well-being for hospitalized blood disease patients.
- What could go wrong
- This is a small, completed study with only 70 participants, so results may not apply to all patients. The effect on anxiety was not measurable in prior sessions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
70 people
The number who actually took part.
- Started
-
Mar 2019
- Finished
-
Oct 2022
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patient (male or female) ≥18 years old * Hospitalized patient in restricted area than 21 days * Patient with acute leukemia (induction or relapse) * Patient hospitalized for hematopoietic stem cell transplantation * Written Inform consent must be obtained before inclusion and randomization * Patient affiliated to and covered by social security for standard care Exclusion Criteria: * Patient hospitalized for another disease * Inability to receive study information and/or understand/speak French * Inability to give informed consent * Legal incapacity (people in jail) or under supervision (i.e. guardianship or curatorship) * Already include in this study on a previous hospitalization
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Acute leukemia are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University Hospital
Lille, 59045, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Why do some leukemia patients develop dangerous blood clots?
- Tweaking donor cells may shield older transplant patients from a dangerous complication
- Vaccine aims to train immune system against blood cancers
- Aloe vera mouthwash tested against chemotherapy mouth sores
- Can blood tests predict transplant complications?
- Can a Three-Drug combo shield stem cell transplant patients from a dangerous immune attack?